Related Experiment Video
Updated: Mar 3, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin and Prostate Cancer: a New Role for an Old Drug
Jessica Whitburn1, Claire M Edwards2, Prasanna Sooriakumaran2,3
1Nuffield Department of Surgical Sciences, University of Oxford, Botnar Research Centre Old Road, Oxford, OX3 7LD, UK. jesswhitburn@gmail.com.
Purpose Of Review:
Since epidemiological studies first demonstrated a potential positive effect of metformin in reducing cancer incidence and mortality, there has been an increased interest in not only better understanding metformin's mechanisms of action but also in exploring its potential anti-cancer effects. In this review, we aim to summarise the current evidence exploring a role for metformin in prostate cancer therapy.
Recent Findings:
Preclinical studies have demonstrated a number of antineoplastic biological effects via a range of molecular mechanisms. Data from retrospective epidemiological studies in prostate cancer has been mixed; however, there are several clinical trials currently underway evaluating metformin's role as an anti-cancer agent. Early studies have shown benefits of metformin to inhibit cancer cell proliferation and improve metabolic syndrome in prostate cancer patients receiving androgen deprivation therapy (ADT). While the body of evidence to support a role for metformin in prostate cancer therapy is rapidly growing, there is still insufficient data from randomised trials, which are currently still ongoing. However, evidence so far suggests metformin could be a useful adjuvant agent, particularly in patients on ADT.
Insights
Metformin shows potential as an anti-cancer agent, particularly for prostate cancer. Ongoing trials are evaluating its effectiveness, especially as an adjuvant therapy alongside androgen deprivation therapy (ADT).
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Epidemiological studies suggest metformin may reduce cancer incidence and mortality.
- Growing interest in understanding metformin's anti-cancer mechanisms and therapeutic potential.
Purpose of the Study:
- To review current evidence on metformin's role in prostate cancer therapy.
- To explore metformin's potential as an anti-cancer agent in prostate cancer treatment.
Main Methods:
- Review of preclinical studies on metformin's antineoplastic effects.
- Analysis of retrospective epidemiological data in prostate cancer.
- Evaluation of ongoing clinical trials investigating metformin's efficacy.
Main Results:
- Preclinical studies show metformin has antineoplastic effects via various molecular mechanisms.
- Epidemiological data for prostate cancer is mixed, but clinical trials are underway.
- Early studies indicate metformin can inhibit cancer cell proliferation and improve metabolic syndrome in patients on androgen deprivation therapy (ADT).
Conclusions:
- Evidence for metformin in prostate cancer therapy is rapidly accumulating.
- Randomized trial data is still pending, but metformin shows promise as an adjuvant agent, especially for patients on ADT.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Psychoneuroimmunology: Diabetes and Cancer

